ArticleBMC infectious diseases2026
Pattern of treatment outcome and safety of prednisolone in the treatment of leprosy reactions among leprosy patients in ALERT hospital: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeprosy reaction is inflammation caused by the body’s immune system attacking the leprosy bacteria. If left untreated or improperly managed, it may lead to irreversible nerve damage, causing mortality, disability, and physical deformities. Oral prednisolone is a recommended drug to manage these reactions. Despite this, the treatment outcome and safety of prednisolone in treating leprosy reactions in clinical practices have not studied well. Thus, this study aimed to assess the status and factors of treatment outcomes and safety of prednisolone in the treatment of leprosy reactions.
methodsA hospital-based retrospective cohort study was conducted. Data were collected using a data abstract form, entered into Epi-Data version 4.0, and then exported to SPSS version 25 for further analysis. Descriptive statistics were computed to get summary results, and binary and multinomial logistic regression analyses were used to predict factors that affect the treatment outcome and safety of prednisolone.
resultsIn this study, 262 patients’ record files were reviewed. The median age of patients was 30 (IQR 25–42.5) years. Two-thirds (66.8%) of patients were males. Of 262, only 62.2% of the patients improved from the leprosy reactions with prednisolone treatment. Patients with WHO disability grade-0 showed more improvement than those with higher grades. Furthermore, out of 262 patients, 79.4% experienced at least one adverse event during the course of treatment. The starting dose of prednisolone and treatment duration were significantly associated with the occurrence of the adverse events.
conclusionA considerable proportion of the patients didn’t show improvement in their reaction status with prednisolone for both type one and two reactions. The prevalence of adverse events was higher, and the magnitude was proportional to duration and dose of prednisolone, suggesting the need to optimize treatment strategies. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.